Palvella Therapeutics (PVLA) Total Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Total Liabilities data on file, last reported at $31.4 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 31.78% year-over-year to $31.4 million in Q1 2026; TTM through Mar 2026 was $31.4 million, a 31.78% increase from a year earlier, with the FY2025 full-year figure at $31.6 million, up 23.21% from the prior year.
• Total Liabilities for Q1 2026 stood at $31.4 million, roughly flat from $31.6 million in the prior quarter.
• Over the last five years, Total Liabilities for PVLA reached as high as $83.7 million in Q1 2022 and fell as low as $11.4 million in Q4 2023.
• Historically, Total Liabilities has averaged $40.0 million across 5 years, with a median of $29.5 million in 2024.
• Across the five-year window, Total Liabilities tumbled 83.08% in 2023 and soared 124.25% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $67.6 million in 2022, then tumbled by 83.08% to $11.4 million in 2023, then surged by 124.25% to $25.6 million in 2024, then rose by 23.21% to $31.6 million in 2025, then fell by 0.41% to $31.4 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $31.4 million in Q1 2026, $31.6 million in Q4 2025, and $28.3 million in Q3 2025.